Tumor suppressor gene

Expression profile of tumor suppressor gene RASSF1 in lacrimal gland carcinoma

C. H. Zeng, Guo, B., Chen, J., He, W. M., and Luo, Q. L., Expression profile of tumor suppressor gene RASSF1 in lacrimal gland carcinoma, vol. 14, pp. 6993-6998, 2015.

We examined the expression pattern of the tumor sup­pressor gene RAS association domain family gene 1 (RASSF1) in lacri­mal gland carcinoma and analyzed its relationship with the oncogenesis and progression of tumors. Sixty-two patients (30 males, 32 females, average age = 47 ± 3.5 years) admitted with lacrimal gland carcinoma to the Department of Ophthalmology of our hospital between January 2012 and January 2014 were enrolled in this study. Based on tumor ma­lignancy, patients were classified into a malignant group (N = 25) and benign group (N = 37).

NPRL2 gene expression in the progression of colon tumors

B. Yogurtcu, Hatemi, I., Aydin, I., and Buyru, N., NPRL2 gene expression in the progression of colon tumors, vol. 11, pp. 4810-4816, 2013.

Genetic and epigenetic factors affecting DNA methylation and gene expression are known to be involved in the development of colon cancer, but the full range of genetic alterations and many key genes involved in the pathogenesis of colon cancer remain to be identified. NPRL2 is a candidate tumor suppressor gene identified in the human chromosome 3p21.3 region. We evaluated the role of this gene in the pathogenesis of colorectal cancer by investigating NPRL2 mRNA expression in 55 matched normal and tumor colon tissue samples using quantitative RT-PCR analysis.

Subscribe to Tumor suppressor gene